Strong revenue beat, specialty scaling, but margin quality mixed
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Prior FY27 20% growth guidance exceeded (51% delivered). US 25-30% beat 35%. Debt reduction on track (₹102 Cr in H1 vs ₹300-500 Cr target).
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue beat (+51% YoY) and specialty scaling momentum offset by volatile margin quality (non-recurring items, consumer losses ₹4.5 Cr). Guidance reaffirmed but execution risk on new product approvals and consumer profitability remains.
₹1387.9 Cr
Revenue · +51% YoY₹98.6 Cr
Reported PAT · +111.1% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue 51% YoY growth, EBITDA 38% growth
METRevenue ₹1387.9 Cr +51%, EBITDA ₹177 Cr vs ₹128 Cr Q2 FY26 (+38%)
US films business grew 35% in Q2, ahead of prior 25-30% guidance
METManagement stated 35% growth volume terms, up from prior ~50M target; corroborated by earlier call comments
Specialty chemicals H1'27 revenue ~₹155 Cr, growing 59%
UnverifiedSpecialty revenue growth 59% H1, but absolute ₹155 Cr figure not in delivered results; plausible from segment math
Plastech H1'27 revenue ₹75 Cr, growing 73%
UnverifiedStated in call; specific figure not cross-checked against delivered results
Net debt reduced ₹102 Cr in H1, tracking debt reduction target
METSep 26 net debt ₹1057 Cr vs March ₹1159 Cr = ₹102 Cr reduction; target ₹300-500 Cr over 2 years
Cosmo Consumer 70% growth Q2, Zigly 47% growth
UnverifiedManagement stated both figures; not in consolidated delivered results but plausible for segments
Earnings quality
What changed since the last call
US films growth guidance beaten
UpgradePrior call: 25-30% growth. Q2 delivery: 35% volume growth. Management confident to exceed $100M next year.
Specialty volume growth acceleration
UpgradeH1'27 specialty growth 20% YoY vs historical 10% CAGR. 59% growth in specialty chemicals (H1'27) is material acceleration.
Debt trajectory reaffirmed
NeutralPrior target: ₹400-500 Cr reduction over 2 years. Current: ₹300-500 Cr (slight range widening, on track; ₹102 Cr in H1).
Consumer business losses expected to persist
NewCosmo Consumer EBITDA loss ₹4.5 Cr Q2, management budgeting losses for 2 years (brand phase). First disclosed as material item this call.
The Q&A
Analysts pressed hard on BOPP/BOPET margin reconciliation (Aman Agarwal), specialty % mix targets (Saransh Gupta), and new product capex (Kevin Gandhi). Management held firm on per-kg numbers, clarity on seasonality. Limited evasion except on Zigly transaction (said exploring options, no update).
US films growth outlook — Nirav Jimudia, Anvil Wealth
Answered35% growth Q2, target >$100M this FY. 8-10% capacity upside still available. 1.5-2 new BOPP lines planned over 2 years.
BOPP margin reconciliation — Aman Agarwal, Nuvama AMC
AnsweredQ2 included ₹7 Cr inventory loss. Excluding that, reconciliation visible. Margins aligned Q1-Q2 on apples-to-apples.
Specialty mix and margin targets — Saransh Gupta, SVAN Investments
PartialSpecialty growth multiple vectors: packaging, labels, graphics. Consumer break-even depends on marketing spend. Targeting brand maturity in 2 years, then margin ramp.
New capex value addition — Abhijit, 129 Wealth
AnsweredCoating adds US$0.70-1.00 per kg value. Currently using own substrate, open to other sources. Commissioning H2FY27.
Raw material volatility and inventory risk — Abhijit, 129 Wealth
AnsweredRaw prices moved up further this month. Volatility persists (West Asia crisis). Timing of reversal unpredictable.
Korea/Japan specialty expansion — Anil Nahata, Parami Financial
AnsweredJoint venture Korea, own team Japan. Both high-margin. Approvals take 3-5 years. Phased entry, customer retention high.
Zigly transaction status — Aman Agarwal, Nuvama AMC
DodgedStill evaluating options to unlock value. No concrete timeline. Will update when concrete.
Consumer business profitability path — Saransh Gupta, SVAN Investments
PartialContinuing 2-year marketing investment (₹4 Cr Q2). Break-even flexible based on brand build. No fixed timeline, prefers quality maturity.
Guidance
FY27 topline growth ~20%, specialty mix 60-65% (target 65-70% by FY28)
HighQ2 already +51% YoY. Management confident specialty will drive. H1 specialty 20% growth supports.
US films to exceed $100M this FY, sustain 25-30%+ growth
HighQ2 +35% volume already ahead. 8-10% capacity upside remains. 1.5-2 new lines planned 2-year horizon.
Specialty mix 65-70% target FY28, with multiple product verticals (packaging, labels, graphics, coating, barrier sheet)
MediumNew capex (16K tons coating, 10K tons barrier) in H2 execution-dependent. Customer approvals 3-5 years for high-margin niches.
Specialty film margins to expand via product mix (coating, barrier sheet value add US$0.70-1.00 per kg)
MediumNew lines ramp H2 FY27. Barrier sheet 20%+ margins. Coating adds value on base film. Depends on approvals, customer traction.
EBITDA margin (core) to improve on specialty %, despite consumer losses (2-year phase)
MediumQ2 core EBITDA 12.8% (excl non-recurring). Consumer drag ₹4.5 Cr temporary. Renewable power adds 1-1.5% margin post-FY28.
FY27 CAPEX ₹100-110 Cr (specialty capex focused). FY28+ maintenance + modest growth capex
HighCoating line + barrier sheet included in FY27 spend. No new BOPP capex imminent. Focus on specialty ROI and capacity utilization.
Risks the call surfaced
Raw material volatility
MediumOil-linked inputs (polypropylene, polyester) volatile due to West Asia. Q2 included ₹7 Cr inventory loss. Further reversals possible if prices correct.
Consumer business loss trajectory
MediumCosmo Consumer EBITDA loss ₹4.5 Cr Q2 (₹4 Cr ad spend). Management expects 2-year loss phase. Zigly growing 47% but profitability path unclear.
New product approval timelines
MediumCoating line (16K tons) and barrier sheet (10K tons) capex depend on customer approvals. Korea/Japan approvals take 3-5 years. Capex at risk if demand doesn't materialize.
Debt and leverage
LowNet debt ₹1057 Cr (1.9x EBITDA) remains elevated. Reduction target ₹300-500 Cr over 2 years ambitious if EBITDA growth slows.
Margin compression from specialty mix transition
LowCoating and barrier sheet lines are high-margin long-term but require ramp volumes. Early adoption margin profile may disappoint if customer mix heavy on lower-margin initial orders.
Management
Score 7/10. Clear and structured. CFO (Neeraj Jain) drilled into per-kg margins, volume %, and segment EBITDA. CEO (Ashok Jaipuria) articulate on strategy (specialty focus, new verticals). Candid on challenges (consumer losses, raw volatility). Track record solid: FY27 guidance 20% beat (51% Q2), US 25-30% beat (35%), debt reduction on track (₹100 Cr H1). New capex (coating, barrier sheet) on schedule for H2 ramp. Specialty growth 20% H1 vs 10% historical CAGR.
1 · H2 FY27
16,000 tons specialty coating line + 9-layer barrier sheet ramp (10,000 tons capacity)
2 · Q3-Q4 FY27
Cosmo Consumer target break-even after ₹4 Cr marketing spend Q2-H1; Zigly transaction clarity
3 · FY28
Renewable power to 2/3 of supply (₹25-30 Cr cost savings). Japan/Korea approvals for specialty products.
Guidance reaffirmed but execution risk on new product approvals and consumer profitability remains.
Informational and educational content only. Not investment advice.